New study published in The Lancet shows Trimbow® superiority over Ultibro® Breezhaler®

· The TRIBUTE study showed superiority of Chiesi’s triple extrafine formulation Trimbow® over Ultibro® Breezhaler® (indacaterol/glycopyrronium bromide) in terms of moderate to severe exacerbations, lung function and health-related quality of life in patients affected by Chronic Obstructive Pulmonary Disease (COPD) · Chiesi’s triple extrafine formulation significantly reduced the rate of moderate to severe exacerbation, compared to indacaterol/glycopyrronium bromide with a similar safety profile (including pneumonia). · Results published in the Lancet may have important implications